In this multicenter, retrospective cohort study, we evaluated the clinical impact of bilirubin on the survival of patients with EGFR-mutated NSCLC who received EGFR-TKI therapy in a discovery cohort and validated the results in an independent cohort. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.